Cardiovascular and Endothelial Disease in HIV Infection

As combination antiretroviral therapy improves outcome for HIV-infected patients, more focus is directed on the durability of these regimens and the prevention of long-term adverse events. Given the prevalence of metabolic complications associated with combination therapy, namely insulin resistance,...

Full description

Saved in:
Bibliographic Details
Published inCurrent infectious disease reports Vol. 7; no. 4; pp. 309 - 315
Main Authors Cespedes, Michelle S, Aberg, Judith A
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 01.07.2005
Subjects
Antiretroviral drugs
Biomarkers
Cardiovascular disease
HIV
Human immunodeficiency virus
Infectious diseases
Risk factors
Online AccessGet full text

Cover

More Information
Summary:As combination antiretroviral therapy improves outcome for HIV-infected patients, more focus is directed on the durability of these regimens and the prevention of long-term adverse events. Given the prevalence of metabolic complications associated with combination therapy, namely insulin resistance, dyslipidemia, and truncal adiposity, interest in whether these complications predispose patients to cardiovascular disease prematurely is appropriate. This paper reviews the most recent data regarding the effects of HIV and its treatment on endothelial dysfunction, serum biomarkers, and vascular indices, and provides an update on the risk for cardiovascular events in the HIV-infected patient population.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1523-3847
1534-3146
DOI:10.1007/s11908-005-0064-3